Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Equity Research

 

Commissioned research by Vator Securities is offered to selected life science companies – “By Invitation Only”

 

Commissioned research: Immunovia AB

The news flow from Immunovia will be very intense and important in the coming months and quarters.

Regarding the company’s lead asset, IMMray PanCan-d, the last phase of the optimisation of the commercial signature and algorithm is ongoing, and results from the 1,600-sample test is planned to be reported by early June.

Commissioned research: AlzeCure Pharma

AlzeCure’s lead product asset, ACD855, started clinical development in late 2018 with the ambition to generate first clinical trials by early 2020.

However, early human exposure with the tablet product demonstrated that the concentration of the substance would require significantly longer dosing intervals than once daily, so the future development of the substance will now only be pursued with a formulation targeting ophthalmologic disorders.

Commissioned Research: Ascelia Pharma AB

Ascelia Pharma is a Swedish based oncology company in late-stage development with a primary focus on contrast enhanced liver MRI for those with severely impaired kidney function.

The company’s management has extensive experience from rare diseases at large corporations, including Genzyme (acquired by Sanofi) and Wilson Therapeutics (acquired by Alexion).

Commissioned Research: Bio-Works Technologies AB

Bio-Works is a Swedish-based supplier to biopharmaceutical producers, serving early-stage lab-scale to full-scale commercial producers. Its niche is the market for separation media used in protein purification.

The company started commercial sales in 2014. Market demand is driven by increased production volumes of biopharmaceutical products including biosimilars, and productivity investments.

Commissioned research: Immunovia AB

Immunovia is a Swedish-based diagnostic company in late-stage development for products for early detection of diseases within the oncology and autoimmune areas, with a primary target on early detection of pancreas cancer.

The company’s management team has extensive diagnostics company background, including GE Healthcare and DAKO (aquired by Agilent)

Commissioned research: AlzeCure Pharma

AlzeCure Pharma is a Swedish-based pharmaceutical company with potentially first-in-class proprietary and novel targeted small molecule (tablets) candidates for neurodegenerative diseases with a primary target on Alzheimer’s Disease (AD).

AlzeCure’s management team has extensive big pharma experience, and formed an integral part of AstraZeneca’s CNS department.